Ionis Pharmaceuticals, Inc. (0JDI.L)
| Previous close | 41.00 |
| Open | 40.52 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 40.52 - 40.75 |
| 52-week range | 33.21 - 53.94 |
| Volume | |
| Avg. volume | 351 |
| Market cap | 56.445M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Ionis reports first quarter 2024 financial results
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter ended March 31, 2024.
- PR Newswire
Ionis Publishes 2023 Corporate Responsibility Report
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report details Ionis' relentless passion to create better futures for people touched by serious disease as well as other stakeholders. In 2023, Ionis extended its commitment to corporate responsibility (CR) through the establishment of three strategic pillars with actionable goals. Ionis also committed to continuing to transparently communicate the Company's pr
- PR Newswire
Ionis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
